Harvey Norman shopfront
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Harvey Norman (ASX:HVN) shares were up +0.62% to $4.85/sh heading into lunchtime in Sydney on Wednesday – even as Echo Law’s class action against the company kicks off.

Customers who purchased Harvey Norman’s extended warranty product ‘Product Care’ between 17 September 2018 and 17 September 2024 are eligible to join. That goes too for customers at Domayne or Joyce Mayne.

The company is ultimately alleged to have knowingly issued junk warranties to Australian consumers who thereby paid, in essence, for nothing – a breach of Australian Consumer Law (ACL).

ACL is important here – because the Product Care product Harvey Norman sold was already covered by ACL, which Australians are born with an inherent right to be protected by, much like copyright.

In essence: Harvey Norman pocketed cash in exchange for something consumers already had.

According to industry reports, lawyers are representing Australian consumers who collectively made hundreds of millions of dollars worth of purchases for Product Care warranties.

Harvey Norman has not issued any statement on the matter as at lunchtime Sydney time on Wednesday, either ASX-facing or otherwise.

Its last document to hit the bourse was a corporate governance statement on the 9th of September – which could, perhaps, cause a smirk to form.

It’s not the first time Harvey Norman has been told off, either. Back in 2022 ASIC came after Harvey and Latitude Finance Australia over allegations they misled consumers on claims of “interest free” payments.

HVN last traded at $4.85.

hvn by the numbers
More From The Market Online
The Market Online Video

Market Close: ASX 200 rallies as risk appetite returns, but business confidence weakens

The Australian sharemarket finished firmly higher today with the S&P/ASX 200 adding 106.50 points, or 1.18%, to close at 9,136.20.

EVE Health Group signs Australian compounding agreement for rapidly rising Men’s Health issue

EVE Health Group has signed an agreement with Optimal Pharmacy Plus Stafford aimed at the Australian…

Nanoveu’s EMASS signs DigiKey as Global Distributor for ECS-DoT-22

Nanoveu's wholly-owned subsidiary EMASS has signed DigiKey as its global distributor for ECS-DoT-22 system.
The Market Online Video

Wealth Within: Wall Street Tech Sinks While ASX Tech Soars

Wall Street’s technology stocks have been hammered, with the Nasdaq plunging 5.5 per cent in a single session and Nvidia falling more tha…